Senti Biosciences to Showcase New Cell & Gene Therapy Data at AACR Annual Meeting 2025

Senti Biosciences, Inc. (Nasdaq: SNTI), a clinical-stage biotechnology company developing next-generation cell and gene therapies with its proprietary Gene Circuit platform, announced the selection of three abstracts for an oral minisymposium and poster presentations at the American Association for Cancer Research (AACR) Annual Meeting 2025, scheduled for April 25–30, 2025, at the McCormick Place Convention Center in Chicago, IL.

Presentations to Highlight SENTI-202 Clinical and Preclinical Data

Senti Bio will present new clinical data from its first-in-human, multicenter study of SENTI-202, an off-the-shelf, logic-gated CAR NK cell therapy targeting CD33 and FLT3 in hematologic malignancies, including acute myeloid leukemia (AML). The organizers scheduled the oral presentation for Sunday, April 27, 2025, at 4:30 PM CST during the Clinical Trials Oral Minisymposium (Session CTMS01 – ADCs and Immuno-oncology-focused Biological Approaches). They will announce the location closer to the event, and they assigned the abstract number CT041.

Researchers will share additional correlative data from the SENTI-202 study during a poster session on Tuesday, April 29, 2025, from 9:00 AM to 12:00 PM CST. This presentation is part of the “First-in-Human Phase I Clinical Trials 2” session (PO.CT01.02) and will take place in Section 48. The abstract is listed as CT143 / 9.

Senti Biosciences will also highlight preclinical findings demonstrating that SENTI-202’s CD33 OR FLT3 NOT EMCN logic-gated gene circuit components selectively target AML cells while sparing healthy human hematopoietic stem and progenitor cells (HSC/HPCs) from off-tumor toxicity. Researchers will present this data during a poster session under the Immunology track, titled “Novel In Vivo, In Vitro, and In Silico Models” (Session PO.IM01.17), on Wednesday, April 30, 2025, from 9:00 AM to 12:00 PM CT in Section 38. They assigned the abstract number 7271 / 18.

Advancing Gene Circuit-Enabled Cell Therapies for Hematologic and Solid Tumors with Promising Early Clinical Results

Senti Bio engineers its Gene Circuits to selectively kill cancer cells, spare healthy tissue, enhance target specificity, and regulate therapeutic activity after administration. The company’s pipeline includes off-the-shelf CAR-NK cell therapies equipped with Gene Circuits to address both liquid and solid tumors. Its lead candidate, SENTI-202, a logic-gated CD33 and/or FLT3-targeting therapy for hematologic cancers, achieved MRD-negative complete remissions in two out of three patients as of September 19, 2024, with remissions sustained for more than six months as of March 20, 2025. Senti Bio has also shown in preclinical studies that its Gene Circuits can function in T cells, enabling selective targeting of solid tumors, and demonstrated the potential application of Gene Circuits across other cell and gene therapy platforms and non-oncology diseases, which the company continues to explore through internal programs and external partnerships.

Kanya Rajangam, MD, PhD, President, Head of R&D and Chief Medical Officer of Senti Bio said, “We are excited to present updated clinical and correlative data from our ongoing SENTI-202 trial, along with detailed preclinical characterization of our Logic Gate technology. The preclinical data shows the EMCN inhibitory CAR (our NOT gate) protects healthy bone marrow cells from on-target off-tumor toxicity in vivo. Taken together, this data continues to support our enthusiasm for the potential of SENTI-202 to treat r/r AML and for Logic Gating, including our unique NOT gates, to be broadly applied to oncology to enhance the selective targeting of cancer while sparing healthy cells that may express the same targets.”

Related posts:

Study Shows ctDNA Liquid Biopsy Detects Colorectal Cancer Recurrence Earlier Than Imaging AI-Based Model Accurately Classifies Pediatric Sarcomas Using Digital Pathology Images AI-Driven Model Enhances Cancer Cachexia Prediction by Integrating Imaging and Clinical Data AACR Annual Meeting 2025: Cancer Research Innovations, NIH Funding Advocacy, and AI-Driven Advances

Author

Denisse Sandoval